MMRGlobal Announces Claim Construction Order Adopts Six of Eight Plaintiff Proposed Claim Terms

LOS ANGELES, CA--(Marketwired - Sep 8, 2014) - MMRGlobal, Inc. (OTCQB: MMRF), through its wholly owned subsidiary MyMedicalRecords, Inc. (collectively, "MMR"), today announced that on September 3, 2014, a Claim Construction Order was issued in the consolidated patent infringement suits between plaintiff MyMedicalRecords, Inc., and defendant(s) Quest Diagnostics, Inc., Empty Jar, LLC f/k/a Jardogs, LLC, Allscripts Healthcare Solutions, Inc., and WebMD Health Corp. and WebMD Health Services Group. MMR now looks forward to proceeding with discovery and preparing for trial.

At issue were claim constructions for eight different terms found in either U.S. Patent No. 8,301,466 ("the '466 patent"), U.S. Patent No. 8,498,883 ("the '883 patent"), or both. Of the eight claim terms in dispute, the Court ruled that the plain and ordinary meaning should be applied to six of the terms. In its order, the Court also adopted constructions favorable to MMR for key terms in dispute with respect to the '466 patent by affording the terms of their plain and ordinary meaning. The Company believes that the Court Order affirms the relevance of the '466 patent and the Company's intellectual property portfolio.

MMR also believes the Claim Construction Order helps identify additional licensing opportunities for its 13 issued U.S. health information technology patents including its recently received Clinical Trials patent as well as in continuing its prosecution of 17 pending applications in the U.S. and 34 issued and pending health IT patents in countries of commercial interest around the world.

The order follows a consolidated Markman Hearing held in the United States District Court for the Central District of California on August 19, 2014. MMR also feels fortunate to have received this ruling within weeks following the Markman Hearing and prior to proceeding with discovery which should enable the Company to focus discovery on the most relevant issues in the cases at this time.

MyMedicalRecords, Inc. is a practicing entity and a leading provider of secure and easy-to-use Personal Health Records through its MyMedicalRecords PHR, and MMRPro document management and imaging systems for healthcare professionals. MMR currently has 13 issued U.S. health IT patents including U.S. Patent Nos. 8,301,466; 8,352,287; 8,352,288; 8,121,855; 8,117,646; 8,117,045; 8,321,240; 8,498,883; 8,626,532, 8,645,161; 8,725,537; 8,768,725 and 8,775,212, as well as additional applications and continuation applications involving inventions pertaining to Personal Health Records, Patient Portals and other Electronic Health Record systems. In addition to the U.S., MMR currently has patents issued, pending and/or applied for in 11 other countries or regional authorities including Australia, Singapore, New Zealand, Mexico, Japan, Canada, Hong Kong, China, South Korea, Israel and Europe.

MMRGlobal also owns a biotechnology portfolio of patents and patent applications for its monoclonal antibody technology, including patents and applications covering anti-CD20 antibodies and their production. U.S. Patent No. 8,465,741, in particular, protects various antibodies and the methods for making and using them; and additional U.S. patent applications are pending. Foreign protection includes patents in Australia, South Korea and Mexico, along with pending applications in Brazil, Canada, China, Hong Kong, India, Europe, and Japan, all originating from international application PCT/US07/78568. The patents provide further detail of the development, structure, manufacture and established assays belonging to MMRGlobal.

The Court's ruling on a seventh claim term found in the asserted claims of the '883 patent affects only one claim in the patent. The '883 patent contains numerous additional independent claims. None of these additional claims appear to be affected by the ruling. Accordingly, the '883 patent remains with numerous additional independent claims.

About MMRGlobal
MMRGlobal, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc., provides secure and easy-to-use online Personal Health Records ("PHRs") and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, retail pharmacies, and professional organizations and affinity groups. The MyMedicalRecords PHR enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. MyMedicalRecords is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user's account. MMR's professional offering, MMRPro, is designed to give physicians' offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients through an integrated patient portal. Through its merger with Favrille, Inc. in January 2009, MMR acquired intellectual property biotech assets that include anti-CD20 antibodies and data and samples from its FavId™/Specifid™ vaccine clinical trials for the treatment of B-Cell Non-Hodgkin's lymphoma. To learn more about MMRGlobal, Inc. visit www.mmrglobal.com. View demos and video tutorials of MMR's products and services at www.mmrtheater.com. Follow us on Facebook.com/MMRGlobal and Twitter.com/mmrglobal.

Forward-Looking Statements
All statements in this release that are not strictly historical facts are "forward-looking statements." Such forward-looking statements are based on MMR's current assumptions, beliefs and expectations, and involve risks, uncertainties and other factors that may cause MMR's actual results to be materially different from any results expressed or implied by such forward-looking statements. Some can be identified by the use of words such as "expect," "plan," "possibility," "offer," "if," "negotiate," "when," "believe," "will," "estimate," "continue," and similar expressions. Risks, uncertainties, and other factors that could cause or contribute to such differences include, but are not limited to: ongoing and future intellectual property enforcement actions; the ability to successfully litigate or settle claims of patent infringement; MMR's ability to develop, license and monetize its patents in the portfolio for both MMR's health IT and biotechnology IP assets; reliance upon the successful operations of its business partners in selling MMR's products and services, the timing of milestone payments in connection with licensing its IP; MMR's ability to obtain necessary financing, generate sufficient cash flow, and maintain appropriate indebtedness; and the increasing development of market competition in the area of electronic records in clinical trials. These factors and others are described in more detail in MMR's public filings with the Securities and Exchange Commission, including the risks discussed in the "Risk Factors" section in MMR's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Copies of these reports can be found on MMR's website (www.mmrglobal.com) under the heading "Investor Relations." MMR is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.